SARS-CoV-2 infection in 898 patients with Sjögren’s syndrome: characteristics associated with poor outcomes
Flores-Chavez et al.,
SARS-CoV-2 infection in 898 patients with Sjögren’s syndrome: characteristics associated with poor outcomes,
Clinical and Experimental Rheumatology, doi:10.55563/clinexprheumatol/pt3syo
Retrospective 898 patients with Sjögren’s disease, showing a lower risk of worse outcomes with HCQ compared to corticosteroids, immunosuppressive agents, and B-cell depleting agents.
Flores-Chavez et al., 1 Sep 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Italy, peer-reviewed, survey, mean age 56.0, 1 author.
Abstract: Congress Chairperson
Salvatore De Vita
Clinic of Rheumatology, ASUFC,
University of Udine, Italy
Young Co-Chairpersons
Chiara Baldini, Pisa, Italy
Luca Quartuccio, Udine, Italy
Scientific Committee
A. Baer, USA
C. Baldini, Italy
E. Bartoloni Bocci, Italy
S. Bombardieri, Italy
M. Bombardieri, UK
H. Bootsma, The Netherlands
S.J. Bowman, UK
L.A. Criswell, USA
S. De Vita, Italy
T. Dörner, Germany
C. Fabro, Italy
R.I. Fox, USA
V. Manfrè, Italy
X. Mariette, France
J.O. Pers, France
L. Quartuccio, Italy
M. Ramos Casals, Spain
E. Treppo, Italy
A.G.Tzioufas, Greece
A. Zabotti, Italy
Clinical and Experimental Rheumatology 2022
Clinical and Experimental Rheumatology 2021
Local Organising Committee
L. Quartuccio, Italy
A. Zabotti, Italy
E. Treppo, Italy
V. Manfrè, Italy
C. Fabro, Italy
E. Bartoloni Bocci, Italy
F. Conti, Italy
R. Gerli, Italy
R. Priori, Italy
G. Valesini, Italy
C. Vitali, Italy
Working Team
S. De Vita, Italy
S. Bombardieri, Italy
A.G. Tzioufas, Greece
H. Bootsma, The Netherlands
C. Baldini, Italy
E. Bartoloni Bocci, Italy
M. Bombardieri, UK
M. Ramos Casals, Spain
T. Dörner, Germany
and consultants:
A. Baer, USA
S.J. Bowman, UK
L.A. Criswell, USA
R.I. Fox, USA
X. Mariette, France
J.O. Pers, France
International Advisory Board
Past Presidents
International Committee
J.M. Anaya, Colombia
E.K. Akpek, USA
M. Bombardieri, UK
H. Bootsma, The Netherlands
S.J. Bowman, UK
S. Carsons, USA
L.A. Criswell, USA
C.S. De Paiva, USA
T. Dörner, Germany
B.A. Fisher, UK
A. Goules, Greece
J.E. Gottenberg, France
S.K. Kwok, Korea
L. Lu, China
X. Mariette, France
T. Mandl, Sweden
C. Mavragani, Greece
W.F. Ng, UK
R. Omdal, Norway
H. Park, Korea
S.C. Plugfelder, USA
M. Ramos Casals, Spain
S. Retamozo, Spain
L. Ronblom, Sweden
A. Rosen, USA
H.A. Saraux, France
H. Scofield, USA
S.C. Shiboski, USA
M. Tomsic, Slovenja
J. Van Roon, The Netherlands
A. Vissink, The Netherlands
F.B. Vivino, USA
M. Wahren-Herlenius, Sweden
A. Baer, USA
S. Bombardieri, Italy
P. Fox, USA
R. Jonsson, Norway
H.M. Moutsopoulos, Greece
A. Parke, USA
J.O. Pers, France
T. Sumida, Japan
A.G. Tzioufas, Greece
P. Youinou, France
Clinical and Experimental Rheumatology 2021
15th International Symposium on Sjögren’s Syndrome
Table of Contents
EXPLORATION OF THE CELLULAR MICROENVIRONMENT IN MINOR SALIVARY GLANDS OF PATIENTS WITH
PRIMARY SJÖGREN´S SYNDROME BY IMAGING MASS CYTOMETRY
Page
10
CCL5 RELEASE BY CCR9+ CD8 T CELLS: A POTENTIAL NOVEL CONTRIBUTOR TO IMMUNOPATHOLOGY OF PRIMARY
SJÖGREN’S SYNDROME
10
B CELL GLYCOSYLATION IN PRIMARY SJÖGREN’S SYNDROME: A NEW POTENTIAL BIOMARKER
10
PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IN A COHORT OF PRIMARY SJÖGREN’S SYNDROME PATIENTS:
A NOVEL MARKER OF DISEASE ACTIVITY?
11
DECIPHERING THE ROLE OF CDC2S IN SJÖGREN’S SYNDROME: TRANSCRIPTOMIC PROFILE LINKS ALTERED
ANTIGEN PROCESSES WITH IFN-SIGNATURE AND AUTOIMMUNITY
11
SINGLE CELL RNA SEQUENCING POINTS TO A ROLE FOR FIBROBLASTS EARLY IN SALIVARY GLAND DYSFUNCTION
IN PRIMARY SJÖGREN’S SYNDROME
11
ABNORMALITIES OF EXTRACELLULAR MATRIX MODELING GENE EXPRESSION IN SALIVARY GLAND EPITHELIAL
CELLS OF PATIENTS WITH SJÖGREN’S SYNDROME
12
LONG NON-CODING RNA HCP5 IS A KEY REGULATOR OF CDC2S FUNCTION: IMPLICATIONS FOR SJÖGREN’S
SYNDROME
12
DEFECTIVE LOCALIZATION AND INTERACTION OF AQUAPORIN-5 INTERACTING PROTEIN PARTNERS IN SALIVARY
GLANDS FROM PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME
13
EXPLORATORY IMMUNOPHENOTYPE OF THE RARE DISEASE JUVENILE SJÖGREN’S SYNDROME REVEALS..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit